Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01659-18. doi: 10.1128/AAC.01659-18. Print 2019 Jan.


Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS.

Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.


Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance.

Chirakul S, Norris MH, Pagdepanichkit S, Somprasong N, Randall LB, Shirley JF, Borlee BR, Lomovskaya O, Tuanyok A, Schweizer HP.

Sci Rep. 2018 Jul 13;8(1):10652. doi: 10.1038/s41598-018-28843-7.


In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.

Zhou M, Yang Q, Lomovskaya O, Sun D, Kudinha T, Xu Z, Zhang G, Chen X, Xu Y.

J Antimicrob Chemother. 2018 Oct 1;73(10):2789-2796. doi: 10.1093/jac/dky251.


Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson KJ, Thamlikitkul V, Dudley MN, Redell MA.

Int J Antimicrob Agents. 2018 Sep;52(3):404-406. doi: 10.1016/j.ijantimicag.2018.04.006. Epub 2018 Apr 14.


Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ.

JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.


Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.

Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01969-17. doi: 10.1128/AAC.01969-17. Print 2018 Feb.


Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.

Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01446-17. doi: 10.1128/AAC.01446-17. Print 2018 Jan.


β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.


In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17. doi: 10.1128/AAC.01904-17. Print 2018 Jan.


Potency of Meropenem-Vaborbactam in Lung Surfactant.

Rubio-Aparicio D, Loutit J, Dudley M, Lomovskaya O.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01702-17. doi: 10.1128/AAC.01702-17. Print 2018 Jan.


Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.

Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01694-17. doi: 10.1128/AAC.01694-17. Print 2017 Dec.


Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov.


Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.

Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, Sebra R, Kasarskis A, Nguyen H, Hanson BM, Leopold S, Weinstock G, Lomovskaya O, Humphries RM.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00989-17. doi: 10.1128/AAC.00989-17. Print 2017 Oct.


Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN.

J Med Chem. 2015 May 14;58(9):3682-92. doi: 10.1021/acs.jmedchem.5b00127. Epub 2015 Mar 17.


Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.

Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH.

Antimicrob Agents Chemother. 2015 May;59(5):2720-5. doi: 10.1128/AAC.04110-14. Epub 2015 Feb 23.


High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an opp oligopeptide permease encoded by the opp-fabI operon.

Mistry A, Warren MS, Cusick JK, Karkhoff-Schweizer RR, Lomovskaya O, Schweizer HP.

Antimicrob Agents Chemother. 2013 Nov;57(11):5565-71. doi: 10.1128/AAC.01198-13. Epub 2013 Aug 26.


Tackling antibiotic resistance.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI.

Nat Rev Microbiol. 2011 Nov 2;9(12):894-6. doi: 10.1038/nrmicro2693. Review.


Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections.

Tsivkovskii R, Sabet M, Tarazi Z, Griffith DC, Lomovskaya O, Dudley MN.

FEMS Immunol Med Microbiol. 2011 Mar;61(2):141-6. doi: 10.1111/j.1574-695X.2010.00755.x. Epub 2010 Nov 12.


Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.

King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN.

Diagn Microbiol Infect Dis. 2010 Feb;66(2):181-6. doi: 10.1016/j.diagmicrobio.2009.09.009. Epub 2009 Oct 13.


In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.

King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN.

Antimicrob Agents Chemother. 2010 Jan;54(1):143-8. doi: 10.1128/AAC.00248-09. Epub 2009 Oct 5.


Drug-induced conformational changes in multidrug efflux transporter AcrB from Haemophilus influenzae.

Dastidar V, Mao W, Lomovskaya O, Zgurskaya HI.

J Bacteriol. 2007 Aug;189(15):5550-8. Epub 2007 May 25.


Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization.

Watkins WJ, Chong L, Cho A, Hilgenkamp R, Ludwikow M, Garizi N, Iqbal N, Barnard J, Singh R, Madsen D, Lolans K, Lomovskaya O, Oza U, Kumaraswamy P, Blecken A, Bai S, Loury DJ, Griffith DC, Dudley MN.

Bioorg Med Chem Lett. 2007 May 15;17(10):2802-6. Epub 2007 Feb 27.


Waltzing transporters and 'the dance macabre' between humans and bacteria.

Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ.

Nat Rev Drug Discov. 2007 Jan;6(1):56-65. Epub 2006 Dec 8. Review.


Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?

Griffith DC, Corcoran E, Lofland D, Lee A, Cho D, Lomovskaya O, Dudley MN.

Antimicrob Agents Chemother. 2006 May;50(5):1628-32.


Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

Lomovskaya O, Bostian KA.

Biochem Pharmacol. 2006 Mar 30;71(7):910-8. Epub 2006 Jan 19. Review.


Vacuuming the periplasm.

Lomovskaya O, Totrov M.

J Bacteriol. 2005 Mar;187(6):1879-83. Review. No abstract available.


Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives.

Watkins WJ, Lemoine RC, Chong L, Cho A, Renau TE, Kuo B, Wong V, Ludwikow M, Garizi N, Iqbal N, Barnard J, Jankowska R, Singh R, Madsen D, Lolans K, Lomovskaya O, Oza U, Dudley MN.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5133-7.


Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (N-methylpiperazine)-containing derivative with activity in clinically relevant Candida spp.

Lemoine RC, Glinka TW, Watkins WJ, Cho A, Yang J, Iqbal N, Singh R, Madsen D, Lolans K, Lomovskaya O, Oza U, Dudley MN.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5127-31.


Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Renau TE, Léger R, Filonova L, Flamme EM, Wang M, Yen R, Madsen D, Griffith D, Chamberland S, Dudley MN, Lee VJ, Lomovskaya O, Watkins WJ, Ohta T, Nakayama K, Ishida Y.

Bioorg Med Chem Lett. 2003 Aug 18;13(16):2755-8.


MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.

Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, Lomovskaya O, Plésiat P.

Antimicrob Agents Chemother. 2003 Apr;47(4):1371-5.


It takes three to tango.

Lomovskaya O, Zgurskaya HI, Nikaido H.

Nat Biotechnol. 2002 Dec;20(12):1210-2. No abstract available.


Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials.

Tegos G, Stermitz FR, Lomovskaya O, Lewis K.

Antimicrob Agents Chemother. 2002 Oct;46(10):3133-41.


Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Renau TE, Léger R, Yen R, She MW, Flamme EM, Sangalang J, Gannon CL, Chamberland S, Lomovskaya O, Lee VJ.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):763-6.


Efflux pumps: their role in antibacterial drug discovery.

Lomovskaya O, Watkins WJ.

Curr Med Chem. 2001 Dec;8(14):1699-711. Review.


Stereochemical elucidation and total synthesis of dihydropacidamycin D, a semisynthetic pacidamycin.

Boojamra CG, Lemoine RC, Lee JC, Léger R, Stein KA, Vernier NG, Magon A, Lomovskaya O, Martin PK, Chamberland S, Lee MD, Hecker SJ, Lee VJ.

J Am Chem Soc. 2001 Feb 7;123(5):870-4.


MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa.

Mao W, Warren MS, Lee A, Mistry A, Lomovskaya O.

Antimicrob Agents Chemother. 2001 Jul;45(7):2001-7.


Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance.

Lee MD, Galazzo JL, Staley AL, Lee JC, Warren MS, Fuernkranz H, Chamberland S, Lomovskaya O, Miller GH.

Farmaco. 2001 Jan-Feb;56(1-2):81-5. Review.


Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria.

Lomovskaya O, Watkins W.

J Mol Microbiol Biotechnol. 2001 Apr;3(2):225-36. Review.


Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Renau TE, Léger R, Flamme EM, She MW, Gannon CL, Mathias KM, Lomovskaya O, Chamberland S, Lee VJ, Ohta T, Nakayama K, Ishida Y.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):663-7.


Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.

Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ.

Antimicrob Agents Chemother. 2001 Jan;45(1):105-16.


Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance.

Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O.

J Bacteriol. 2000 Jun;182(11):3142-50.


Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.

Renau TE, Léger R, Flamme EM, Sangalang J, She MW, Yen R, Gannon CL, Griffith D, Chamberland S, Lomovskaya O, Hecker SJ, Lee VJ, Ohta T, Nakayama K.

J Med Chem. 1999 Dec 2;42(24):4928-31. No abstract available.


Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa.

Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren MS, Boyer E, Chamberland S, Lee VJ.

Antimicrob Agents Chemother. 1999 Jun;43(6):1340-6.


Influence of the TonB energy-coupling protein on efflux-mediated multidrug resistance in Pseudomonas aeruginosa.

Zhao Q, Li XZ, Mistry A, Srikumar R, Zhang L, Lomovskaya O, Poole K.

Antimicrob Agents Chemother. 1998 Sep;42(9):2225-31.


Tn5041: a chimeric mercury resistance transposon closely related to the toluene degradative transposon Tn4651.

Kholodii GY, Yurieva OV, Gorlenko Z, Mindlin SZ, Bass IA, Lomovskaya OL, Kopteva AV, Nikiforov VG.

Microbiology. 1997 Aug;143 ( Pt 8):2549-56.


Differential regulation of the mcb and emr operons of Escherichia coli: role of mcb in multidrug resistance.

Lomovskaya O, Kawai F, Matin A.

Antimicrob Agents Chemother. 1996 Apr;40(4):1050-2.


Regulation of Escherichia coli starvation sigma factor (sigma s) by ClpXP protease.

Schweder T, Lee KH, Lomovskaya O, Matin A.

J Bacteriol. 1996 Jan;178(2):470-6.

Supplemental Content

Loading ...
Support Center